keynote-522: optimal preoperative io and residual disease management in tnbc
Published 6 months ago • 148 plays • Length 1:56Download video MP4
Download video MP3
Similar videos
-
4:20
keynote-522: 5-year follow-up of pembrolizumab in triple-negative breast cancer
-
1:46
exploratory analysis of keynote-522: efs after neoadjuvant pembro chemo vs chemo for early tnbc
-
3:09
keynote-522: neoadjuvant and adjuvant pembrolizumab for early tnbc
-
0:43
management of residual disease in triple negative breast cancer
-
1:03
remaining questions on the use of neoadjuvant pembrolizumab in early tnbc following keynote-522
-
4:20
keynote 522: pembrolizumab as neoadjuvant treatment for early tnbc
-
0:37
management for residual disease in tnbc after chemo-immunotherapy
-
1:03
new directions in immunotherapy for improving outcomes in tnbc
-
5:21
optimal neoadjuvant and adjuvant therapy for patients with early tnbc
-
1:48
residual tumor treatment in mutant brca-1 triple-negative breast cancer
-
9:02
phase 3 keynote-522 results: pembro/chemo neoadjuvant, pembro adjuvant in early tnbc
-
0:50
update on keynote 522, the current standard of care for triple negative breast cancer.
-
1:42
the case for neoadjuvant pembrolizumab in tnbc
-
21:36
treatment planning for triple negative breast cancer | 2022 evolution conference
-
2:05
treatment advances in tnbc
-
1:16
tackling residual disease in breast cancer
-
1:39:18
expanding the benefits of checkpoint inhibitors and targeted agents in triple-negative breast cancer
-
2:53
neoadjuvant chemoimmunotherapy: keynote-522, i-spy & more
-
0:57
a post hoc analysis of adjuvant radiation therapy in the keynote-522 study